Nanocontainers are used globally in diverse fields to encapsulate the cargoes that can potentially overcome various problems associated to different drug delivery systems like stability, solubility, improvement in functional activities, homogeneity and protection from biological and chemical destructions. Following up this approach in the field of biomedicine is considered to be of special importance as it can easily overcome the issues related to biocompatibility, bioavailability, toxicity profile and the therapeutic side effects. Lipid based delivery systems have evolved as a newer approach in the field of drug delivery. Advancement, development and design modification of the lipid based drug delivery systems have given rise to the development of hybrid structures containing both inorganic and organic parts called cerasomes. Cerasomes are basically the modified form of liposomes that are found to overcome limitations related to lipid nanoparticles. However, these cerasomes are also found to be effective in the treatment of diabetes mellitus that is considered to be a metabolic disorder affecting a huge population worldwide since the last few decades. Development of cerasomes for the treatment of diabetes have provided a new window to the researchers to overcome different problems connected to the present therapies. This article provides a thorough assessment of hybrid liposomal cerasome literature and how it can be effectively employed in the treatment of diabetes.
Previous Article in event
Next Article in event
The promising shadow of nanohybrid liposomal Cerasomes towards the treatment of Diabetes Mellitus
Published: 17 February 2022 by MDPI in The 2nd International Electronic Conference on Healthcare session Regenerative Medicine
Keywords: Diabetes mellitus, nanocarriers, phospholipid membrane, biocompatibility, nanoparticles, cerasomes etc.